


Phase IIIb COMBI-APlus

COMBI-APlus

Image



2020105

Atkinson, V. et al. Eur. J. Cancer 2022; 163: 79-87
3
10

Atkinson, V. et al. Asia Pac. J. Clin. Oncol. 2016; 12(suppl 7): 5-12
7

¹⁰

Guidelines from Australian melanoma medical oncologists²⁰
COMBI-AD Grade3/4

11

AJCC8**III A**>1mm**III B III C III D**
BRAF V600E/K18

□□□□□□

12 Grade 3/4

□□□□□□

□□□□□□RFS□□□□□

1111

□□□□□□

12 1 12
 Clopper-Pearson 95% CI
 COMBI-AD 435 87 20% Grade 3/4
 20% 95% CI 20%

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □

12 FAS Kaplan-Meier

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □

30

RFS, Relapse Free Survival

1 Atkinson, V. et al. Eur. J. Cancer 2022; 163: 79-87
 3
 10

2 Atkinson, V. et al. Asia Pac. J. Clin. Oncol. 2016; 12[suppl 7]: 5-12

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □

- COMBI-APlus 8.0 95%CI*: 5.9-10.6
- 95%CI 20% COMBI-APlus

Image

n(%)	COMBI-APlus (n=552)	COMBI-AD** (n=435)
発熱イベント発生率 [95%CI]	44 (8.0) [5.9-10.6]	87 (20.0) [16.3-24.1]
Grade3/4の発熱	21 (3.8)	23 (5.3)
発熱による入院	24 (4.3)	46 (10.6)
発熱による治療中止	13 (2.4)	38 (8.7)

*Clopper-Pearson

**

Atkinson, V. et al. Eur. J. Cancer 2022; 163: 79-87
 3
 10

- 552 541 98 374 68 175 32 CPK 154 28
- Grade3 226 39 CPK 32 21
- 81 85 89
- 2 1 1

2020 10 5

Atkinson, V. et al. Eur. J. Cancer 2022; 163: 79-87
 3
 10

Source URL: https://loadtest.pro.novartis.com/products/tafmek/mel/clinical_02